The MiningNewsWire Podcast

• New ETP, Valour Uniswap, will enable institutions and individuals to invest in Uniswap (UNI) as easily as buying shares from their bank or broker
• Uniswap is the world’s largest decentralized exchange, with US$16.2bn USD in market cap and US$5.1bn USD Total Value Locked (TVL) in the protocol¹
• Valour currently has over US$290m in Assets Under Management (AUM) from its existing products
• Trading in Valour Uniswap to begin on Frankfurt stock exchange later this week

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, today announces that its subsidiary Valour Inc. (“Valour“), an issuer of digital asset exchange traded products (“ETPs“), will launch Valour Uniswap (VALOUR UNISWAP – CH1114178846) on the Börse Frankfurt Zertifikate AG (“Frankfurt“). The Valour Uniswap ETP enables investors to gain exposure to UNI, the native token of the world’s largest decentralised exchange, Uniswap, simply and securely, via their bank or broker.

• New ETP, Valour Uniswap, will enable institutions and individuals to invest in Uniswap (UNI) as easily as buying shares from their bank or broker
• Uniswap is the world’s largest decentralized exchange, with US$16.2bn USD in market cap and US$5.1bn USD Total Value Locked (TVL) in the protocol¹
• Valour currently has over US$290m in Assets Under Management (AUM) from its existing products
• Trading in Valour Uniswap to begin on Frankfurt stock exchange later this week

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, today announces that its subsidiary Valour Inc. (“Valour“), an issuer of digital asset exchange traded products (“ETPs“), will launch Valour Uniswap (VALOUR UNISWAP – CH1114178846) on the Börse Frankfurt Zertifikate AG (“Frankfurt“). The Valour Uniswap ETP enables investors to gain exposure to UNI, the native token of the world’s largest decentralised exchange, Uniswap, simply and securely, via their bank or broker.

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, announced today that its wholly owned subsidiary, Valour Inc. (“Valour“), the pioneering issuer of digital asset exchange traded products (“ETPs”), has surpassed US$250 million (equivalent of 2.1 billion Swedish Krona (“SEK”)) in assets under management (“AUM”). This achievement marks an exceptional first ten months of 2021, as AUM increased more than 2560% since the beginning of the year. In the last 30 days, AUM has increased more than US$40m .

To view the full press release, visit https://nnw.fm/qGNKP

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, announced today that its wholly owned subsidiary, Valour Inc. (“Valour“), the pioneering issuer of digital asset exchange traded products (“ETPs”), has surpassed US$250 million (equivalent of 2.1 billion Swedish Krona (“SEK”)) in assets under management (“AUM”). This achievement marks an exceptional first ten months of 2021, as AUM increased more than 2560% since the beginning of the year. In the last 30 days, AUM has increased more than US$40m .

To view the full press release, visit https://nnw.fm/qGNKP

As recently as 2015, the retail sales for alkaline waters, those with a pH between 7.0 and 10.0, were less than $95 million. With consumers taking a more proactive approach towards health, alkaline sales are booming. Industry authority Beverage Marketing Corp. forecasts retail sales in the category to balloon to $1.3 billion by 2023, representing 20% of the entire value-added water category. Drivers abound to support the 42.6% compound annual growth rate for the forecast period, which are undergirding exponential growth for The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), the largest independent alkaline water company in the United States. Major grocers, including Walmart Inc. (NYSE: WMT), BJ’s Wholesale Club Holdings Inc. (NYSE: BJ), Costco Wholesale Corporation (NASDAQ: COST) and the Kroger Company (NYSE: KR), have benefited from and are following the category trend, many bottling their own alkaline brands while stocking their shelves and distribution centers to increase options and meet consumer demand.

As recently as 2015, the retail sales for alkaline waters, those with a pH between 7.0 and 10.0, were less than $95 million. With consumers taking a more proactive approach towards health, alkaline sales are booming. Industry authority Beverage Marketing Corp. forecasts retail sales in the category to balloon to $1.3 billion by 2023, representing 20% of the entire value-added water category. Drivers abound to support the 42.6% compound annual growth rate for the forecast period, which are undergirding exponential growth for The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), the largest independent alkaline water company in the United States. Major grocers, including Walmart Inc. (NYSE: WMT), BJ’s Wholesale Club Holdings Inc. (NYSE: BJ), Costco Wholesale Corporation (NASDAQ: COST) and the Kroger Company (NYSE: KR), have benefited from and are following the category trend, many bottling their own alkaline brands while stocking their shelves and distribution centers to increase options and meet consumer demand.

Today it seems almost unimaginable to wait days or weeks for results from a blood test, but that was the case only a few decades ago. Automated equipment, portable devices and medical innovation have underscored a healthcare evolution that allows for faster diagnoses and subsequent treatment to improve patient outcomes. Innovation remains at the heart of healthcare, keeping up with the times as doctors, patients and insurance companies now expect near-instant results that detect disease at earlier and earlier stages, sometimes even before symptoms present. Early detection and screening have been proven to save lives and billions of dollars, lending to the rise of point-of-care testing (“POCT”), a nascent industry seeing exciting potential. POCT is the wheelhouse for Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) (Profile), whose turnkey POCT-solution-branded HealthTab(TM) delivers real-time results, with the new technology currently being evaluated at leading pharmacies in Canada with North American expansion planned for the future. Harnessing the power of real-world data is an essential piece of the next generation of medical technology as companies such as Abbott Laboratories (NYSE: ABT), Roche Holding AG ADR (OTCQX: RHHBY), IQVIA Holdings Inc. (NYSE: IQV) and Walgreens Boots Alliance Inc. (NASDAQ: WBA) look to remain stewards in helping people live longer, healthier lives.

Today it seems almost unimaginable to wait days or weeks for results from a blood test, but that was the case only a few decades ago. Automated equipment, portable devices and medical innovation have underscored a healthcare evolution that allows for faster diagnoses and subsequent treatment to improve patient outcomes. Innovation remains at the heart of healthcare, keeping up with the times as doctors, patients and insurance companies now expect near-instant results that detect disease at earlier and earlier stages, sometimes even before symptoms present. Early detection and screening have been proven to save lives and billions of dollars, lending to the rise of point-of-care testing (“POCT”), a nascent industry seeing exciting potential. POCT is the wheelhouse for Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) (Profile), whose turnkey POCT-solution-branded HealthTab(TM) delivers real-time results, with the new technology currently being evaluated at leading pharmacies in Canada with North American expansion planned for the future. Harnessing the power of real-world data is an essential piece of the next generation of medical technology as companies such as Abbott Laboratories (NYSE: ABT), Roche Holding AG ADR (OTCQX: RHHBY), IQVIA Holdings Inc. (NYSE: IQV) and Walgreens Boots Alliance Inc. (NASDAQ: WBA) look to remain stewards in helping people live longer, healthier lives.

DeFi Technologies Inc. (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a digital asset investment firm bridging the gap between traditional capital markets and decentralized finance, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers DeFi Technologies’ recent announcement detailing the expansion of its management team.

To hear the audio production, visit: https://www.nnw.fm/BI0rY

To read the original press release, visit: https://nnw.fm/f4w0A

Per the news release, Russell Starr, Executive Chairman of DeFi Technologies, will assume the role of CEO; Diana Biggs, previously CEO of Valour Inc., will be the company’s Chief Strategy Officer; and Johan Wattenstrom, Co-founder and Director of Valour, will serve as the company’s COO.

DeFi Technologies Inc. (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a digital asset investment firm bridging the gap between traditional capital markets and decentralized finance, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers DeFi Technologies’ recent announcement detailing the expansion of its management team.

To hear the audio production, visit: https://www.nnw.fm/BI0rY

To read the original press release, visit: https://nnw.fm/f4w0A

Per the news release, Russell Starr, Executive Chairman of DeFi Technologies, will assume the role of CEO; Diana Biggs, previously CEO of Valour Inc., will be the company’s Chief Strategy Officer; and Johan Wattenstrom, Co-founder and Director of Valour, will serve as the company’s COO.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

To hear the audio production, visit: https://www.nnw.fm/imIah

To read the original press release, visit: https://nnw.fm/QlM2S

“I am extremely pleased with the progress made to-date in this potentially pivotal trial. Our team has been working intensely to open sites in the U.S. and in Europe, understanding where we can best advance this important study,” John Climaco, CEO of CNS Pharmaceuticals, stated in the news release. “With hundreds of potentially competing GBM trials currently enrolling patients, the fact that we've been able to bring these initial sites on-line and get patients enrolled and dosed not only supports our strategic evaluation and selection, but also allows our data demonstrating Berubicin's potential effectiveness to continue to convince the medical community that we have a new drug with impressive potential. With the de-risked profile of Berubicin, its mechanism of action, history of development, encouraging Phase 1 data, and safety in study design, I am personally more optimistic about our work than at any time since joining the company.”

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

To hear the audio production, visit: https://www.nnw.fm/imIah

To read the original press release, visit: https://nnw.fm/QlM2S

“I am extremely pleased with the progress made to-date in this potentially pivotal trial. Our team has been working intensely to open sites in the U.S. and in Europe, understanding where we can best advance this important study,” John Climaco, CEO of CNS Pharmaceuticals, stated in the news release. “With hundreds of potentially competing GBM trials currently enrolling patients, the fact that we've been able to bring these initial sites on-line and get patients enrolled and dosed not only supports our strategic evaluation and selection, but also allows our data demonstrating Berubicin's potential effectiveness to continue to convince the medical community that we have a new drug with impressive potential. With the de-risked profile of Berubicin, its mechanism of action, history of development, encouraging Phase 1 data, and safety in study design, I am personally more optimistic about our work than at any time since joining the company.”

As consumers continue to insist on more healthy options in choices in their lives, the global health drinks market is projected to see consistent, continued growth, with a CAGR of 7.88% during the next five years. That growth will come from all sectors, including convenience store sales, e-commerce orders and the hospitality sector, which is recovering from COVID-19 slowdowns. Bottled water continues to be America’s favorite drink, outselling soda for the first time in 2016 and continuing that feat every year since. Leading the healthy beverage charge are companies, such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), that are eager to innovate as they meet consumers calls for both taste and quality. In the most recent of a string of innovations that have earned WTER the title of largest independent alkaline company in the country, The Alkaline Water Company launched a brand new line of six natural functional waters. Earlier this year, Shaquille O’Neal, NBA Hall of Famer and Papa John’s International (NASDAQ: PZZA) board member, endorsed the company and was named an advisory board member. Other companies looking to innovate and grow in the space include Celsius Holdings Inc. (NASDAQ: CELH), Nestle SA ADR (OTC: NSRGY) and Keurig Dr Pepper Inc. (NASDAQ: KDP).

As consumers continue to insist on more healthy options in choices in their lives, the global health drinks market is projected to see consistent, continued growth, with a CAGR of 7.88% during the next five years. That growth will come from all sectors, including convenience store sales, e-commerce orders and the hospitality sector, which is recovering from COVID-19 slowdowns. Bottled water continues to be America’s favorite drink, outselling soda for the first time in 2016 and continuing that feat every year since. Leading the healthy beverage charge are companies, such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), that are eager to innovate as they meet consumers calls for both taste and quality. In the most recent of a string of innovations that have earned WTER the title of largest independent alkaline company in the country, The Alkaline Water Company launched a brand new line of six natural functional waters. Earlier this year, Shaquille O’Neal, NBA Hall of Famer and Papa John’s International (NASDAQ: PZZA) board member, endorsed the company and was named an advisory board member. Other companies looking to innovate and grow in the space include Celsius Holdings Inc. (NASDAQ: CELH), Nestle SA ADR (OTC: NSRGY) and Keurig Dr Pepper Inc. (NASDAQ: KDP).

When Democrats took control of Capitol Hill during the elections in November 2020, there was growing optimism that federal legalization of cannabis was in the cards for Americans. Nine months into the new administration, progress has been slow in the United States. Latin American (“LATAM”) countries, on the other hand, have moved forward with new laws ending cannabis prohibition and supporting the industry, moves to generate government revenue, cut into illicit sales and bring novel therapeutic options to people in need. Colombia, Mexico and Panama are emerging as global pioneers promoting responsible cannabis commerce, which bodes well for Flora Growth Corp. (NASDAQ: FLGC) (Profile), a company with robust operations in Colombia. These countries are following the example set forth by Canada, which has given rise to some of the legal cannabis’ juggernauts, such as Canopy Growth Corporation (NASDAQ: CGC), Tilray Inc. (NASDAQ: TLRY) and Sundial Growers Inc. (NASDAQ: SNDL), as other companies such as Innovative Industrial Properties Inc. (NYSE: IIPR) lend additional support to the growing market.

As part of the reopening economy, investors should be monitoring several trends in the healthcare space, including several that fall in the “natural wellness” or “natural alternatives” categories.  The COVID-19 pandemic shone a bright light on lifestyle and self-care as people were encouraged, and often mandated, to stay at home. The trend further points to the next phase of cannabis market maturation, dubbed cannabis 3.0, against the backdrop of legislators discussing the Cannabis Administration and Opportunity Act that would create a national market for marijuana. Looking to address this opportunity, BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) (Profile) has been expanding and diversifying its business in 2021 from its core business as a high-capacity cannabis beverage company into a diversified health and wellness company through a number of accretive acquisitions. BevCanna is emerging as a leader among a group of companies, including the Valens Company (TSX: VLNS) (OTCQX: VLNCF), Neptune Wellness Solutions Inc. (NASDAQ: NEPT), NewAge Inc. (NASDAQ: NBEV) and AYR Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF), that are innovating and taking aggressive approaches to capitalize on the growing cannabis consumer trend moving toward a more wholistic wellness lifestyle business.

As part of the reopening economy, investors should be monitoring several trends in the healthcare space, including several that fall in the “natural wellness” or “natural alternatives” categories.  The COVID-19 pandemic shone a bright light on lifestyle and self-care as people were encouraged, and often mandated, to stay at home. The trend further points to the next phase of cannabis market maturation, dubbed cannabis 3.0, against the backdrop of legislators discussing the Cannabis Administration and Opportunity Act that would create a national market for marijuana. Looking to address this opportunity, BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) (Profile) has been expanding and diversifying its business in 2021 from its core business as a high-capacity cannabis beverage company into a diversified health and wellness company through a number of accretive acquisitions. BevCanna is emerging as a leader among a group of companies, including the Valens Company (TSX: VLNS) (OTCQX: VLNCF), Neptune Wellness Solutions Inc. (NASDAQ: NEPT), NewAge Inc. (NASDAQ: NBEV) and AYR Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF), that are innovating and taking aggressive approaches to capitalize on the growing cannabis consumer trend moving toward a more wholistic wellness lifestyle business.

When Democrats took control of Capitol Hill during the elections in November 2020, there was growing optimism that federal legalization of cannabis was in the cards for Americans. Nine months into the new administration, progress has been slow in the United States. Latin American (“LATAM”) countries, on the other hand, have moved forward with new laws ending cannabis prohibition and supporting the industry, moves to generate government revenue, cut into illicit sales and bring novel therapeutic options to people in need. Colombia, Mexico and Panama are emerging as global pioneers promoting responsible cannabis commerce, which bodes well for Flora Growth Corp. (NASDAQ: FLGC) (Profile), a company with robust operations in Colombia. These countries are following the example set forth by Canada, which has given rise to some of the legal cannabis’ juggernauts, such as Canopy Growth Corporation (NASDAQ: CGC), Tilray Inc. (NASDAQ: TLRY) and Sundial Growers Inc. (NASDAQ: SNDL), as other companies such as Innovative Industrial Properties Inc. (NYSE: IIPR) lend additional support to the growing market.

The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-treat mental health diseases, namely depression, addiction, post-traumatic stress disorder and anxiety. As strides are being made on those fronts, a second investment wave is swelling on the horizon that looks to feature expanded indications and bring new therapeutic options to diseases with unmet needs. Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling practices, among other things. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profile) is leading this next wave of psychedelic drug development beyond mental health into chronic pain and eating disorders as the company advances its clinical programs. With a diverse approach, Tryp is joined by a short list of brand name leaders in psychedelics that includes ATAI Life Sciences N.V. (NASDAQ: ATAI), COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) and Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), all of which are making significant strides towards validating the legitimate potential of a wide range of psychedelic-based treatment regimens.

The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-treat mental health diseases, namely depression, addiction, post-traumatic stress disorder and anxiety. As strides are being made on those fronts, a second investment wave is swelling on the horizon that looks to feature expanded indications and bring new therapeutic options to diseases with unmet needs. Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling practices, among other things. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profile) is leading this next wave of psychedelic drug development beyond mental health into chronic pain and eating disorders as the company advances its clinical programs. With a diverse approach, Tryp is joined by a short list of brand name leaders in psychedelics that includes ATAI Life Sciences N.V. (NASDAQ: ATAI), COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) and Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), all of which are making significant strides towards validating the legitimate potential of a wide range of psychedelic-based treatment regimens.